Lv4
580 积分 2021-04-29 加入
Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect
23天前
已完结
Reply to “PD-L1 expression in anaplastic large cell lymphoma”
23天前
已关闭
PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma
23天前
已关闭
Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships
1个月前
已完结
Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report
1个月前
已完结
Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma
1个月前
已完结
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports
1个月前
已完结
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium
1个月前
已完结
PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia
1个月前
已完结
Expression of PD‐1/PD‐L1 in children's classical Hodgkin lymphomas
1个月前
已关闭
皖公网安备34019202002308
